0001493152-23-007365.txt : 20230313 0001493152-23-007365.hdr.sgml : 20230313 20230313090011 ACCESSION NUMBER: 0001493152-23-007365 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230309 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230313 DATE AS OF CHANGE: 20230313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oncotelic Therapeutics, Inc. CENTRAL INDEX KEY: 0000908259 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133679168 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-21990 FILM NUMBER: 23725894 BUSINESS ADDRESS: STREET 1: 29397 AGOURA RD. STREET 2: #107 CITY: AGUORA HILLS STATE: CA ZIP: 91301 BUSINESS PHONE: 650-635-7000 MAIL ADDRESS: STREET 1: 29397 AGOURA RD. STREET 2: #107 CITY: AGUORA HILLS STATE: CA ZIP: 91301 FORMER COMPANY: FORMER CONFORMED NAME: MATEON THERAPEUTICS INC DATE OF NAME CHANGE: 20160613 FORMER COMPANY: FORMER CONFORMED NAME: OXIGENE INC DATE OF NAME CHANGE: 19930628 8-K 1 form8-k.htm
0000908259 false 0000908259 2023-03-09 2023-03-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

March 9, 2023

 

 

 

ONCOTELIC THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-21990   13-3679168

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

29397 Agoura Road, Suite 107

Agoura Hills, CA 91301

(Address of principal executive offices and Zip Code)

 

Registrant’s telephone number, including area code

(650) 635-7000

 

Not applicable.

(Former name or former address, if changed since last report.)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of class   Trading Symbols   Name of each exchange on which registered
N/A   OTLC    

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On March 9, 2023, Oncotelic Therapeutics, Inc. (the “Company”), peer review publication appeared online: Uckun, F.M.; Qazi, S.; Trieu,V. High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma. Cancers 2023, 15, 1676. https://doi.org/10.3390/cancers15061676.

 

Key conclusions:

 

  ● High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem
  ● The TGFβ1 and TGFβ3 isoforms are predictive
  ● Validation of TGFβ2 as therapeutic target

 

Pediatric cancer of the brainstem, including DIPGs, is one of the most aggressive and deadliest childhood brain tumors. In spite of numerous clinical trials of chemotherapeutic agents, immune-oncology drugs, and specific targeted therapies aimed at improving the survival outcome of these patients, little progress has been achieved and the prognosis remains dismal, with a median survival time of approximately 10 months and a two-year survival rate of less than 10 percent.

 

The purpose of the present study was to evaluate the clinical significance of amplified expression levels of transforming growth factor beta 2 (TGFβ2) in the tumor tissue specimens from these patients. Our findings provide the first evidence that high level TGFβ2 expression is associated with a poor treatment outcome. The reported results also support the notion that further evaluation of the clinical potential of new strategies targeting TGFβ2 in pediatric cancer of the brainstem is warranted.

 

“OT-101 is the only TGFβ2 inhibitor that is in late clinical development. As TGFβ1 and TGFβ3 are not prognostic, we believe that previous clinical failures, including bintrafusp alfa, could be rectified by targeting TGFβ2 instead” stated Dr. Vuong Trieu, CEO and Chairman of Oncotelic.

 

A clinical study protocol looking at treatment of pediatric cancer of brainstem with OT-101 has been accepted onto the National Institute for Health and Care Research (“NIHR”) portfolio. NIHR is the British government’s major funder of clinical, public health, social care and translational research.

 

Disclaimer.

 

The information in this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Forward-Looking Statements.

 

This Current Report on Form 8-K may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, (i) statements with respect to the Company’s plans, objectives, expectations and intentions; and (ii) other statements identified by words such as “may”, “could”, “would”, should”, “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans” or similar expressions. Forward-looking statements in this document include, without limitation, statements regarding the Company’s expectations regarding the expectation and timing of AL-101’s approval through its proposed 505(b)(2) applications, whether the Company will complete development of AL-101, and the anticipated use of proceeds therefrom. These statements are based upon the current beliefs and expectations of the Company’s management and may be subject to significant risks and uncertainties; and that no assurances can be given that such expectations shall be fulfilled.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description   Incorporation by reference
         
99.1   Press release   Filed herewith
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)    

 

-2-

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Oncotelic Therapeutics, Inc.
     
Date: Mar 13th , 2023 By: /s/ Vuong Trieu
    Vuong Trieu
    Chief Executive Officer

 

-3-

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem

 

-The TGFβ1 and TGFβ3 isoforms are predictive

 

—Validation of TGFβ2 as therapeutic target

 

AGOURA HILLS, Calif., March 13, 2023 (GLOBE NEWSWIRE) – Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”), a developer of treatments for rare and orphan indications, including Parkinson’s Disease, pancreatic ductal adenocarcinoma, diffuse intrinsic pontine gliomas (“DIPG”), and COVID-19, today announced the publication of High Intra-Tumor Transforming Growth Factor β2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Cancer of the brainstem. Links to the publication can be found below.

 

Uckun, F.M.; Qazi, S.; Trieu,V. High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma. Cancers 2023, 15, 1676. https://doi.org/10.3390/cancers15061676.

 

Pediatric cancer of the brainstem, including DIPGs, is one of the most aggressive and deadliest childhood brain tumors. In spite of numerous clinical trials of chemotherapeutic agents, immune-oncology drugs, and specific targeted therapies aimed at improving the survival outcome of these patients, little progress has been achieved and the prognosis remains dismal, with a median survival time of approximately 10 months and a two-year survival rate of less than 10 percent.

 

The purpose of the present study was to evaluate the clinical significance of amplified expression levels of transforming growth factor beta 2 (TGFβ2) in the tumor tissue specimens from these patients. Our findings provide the first evidence that high level TGFβ2 expression is associated with a poor treatment outcome. The reported results also support the notion that further evaluation of the clinical potential of new strategies targeting TGFβ2 in pediatric cancer of the brainstem is warranted.

 

“OT-101 is the only TGFβ2 inhibitor that is in late clinical development. As TGFβ1 and TGFβ3 are not prognostic, we believe that previous clinical failures, including bintrafusp alfa, could be rectified by targeting TGFβ2 instead” stated Dr. Vuong Trieu, CEO and Chairman of Oncotelic.

 

A clinical study protocol looking at treatment of pediatric cancer of brainstem with OT-101 has been accepted onto the National Institute for Health and Care Research (“NIHR”) portfolio. NIHR is the British government’s major funder of clinical, public health, social care and translational research.

 

About Oncotelic

 

Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and subsequently to Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designations for DIPG,through OT-101 through its 45% joint venture GMP Biotechnology Limited (“GMP Bio”), with Dragon Overseas Capital Limited (“Dragon”); for melanoma (through CA4P); and Acute Myeloid Leukemia (through OXi 4503). Oncotelic also acquired PointR Data Inc. in November 2019 to create a biotechnology company with artificial intelligence capabilities.

 

   

 

 

During the 4th quarter of 2021, Oncotelic acquired AL-101 for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease (“PD”). Over 60,000 new patients are being diagnosed with PD in the United States and currently there are over 1 million patients in the US and expected to increase to over 1.2 million by 2030. In addition, approximately 10 million suffer from this disease globally. https://www.parkinson.org/Understanding-Parkinsons/Statistics. AL-101 is also being developed for Erectile Dysfunction (“ED”). ED is the most prevalent male sexual disorder globally. The percentages of men affected by ED are as follows: 14.3-70% of men aged 60 years, 6.7-48% of men aged 70 years, and 38% of men aged 80 years (Geerkens MJM et al. (2019). Eur Urol Focus. pii: S2405-4569(19)30079-3). However, with the increasing administration of PDE5 inhibitors in clinical practice, it was found that approximately 30-35% of ED patients are treatment failures (McMahon CN et al. (2006). BMJ, 332: 589-92). AL-101 is designed to target treatment failure ED patients who do not respond to PDE5 inhibitors. Through similar mechanism of action, AL-101 is being developed for Female Sexual Dysfunction (“FSD”). Female sexual dysfunction is a prevalent problem, afflicting approximately 40% of women and there are few treatment options. FSD is more typical as women age and is a progressive and widespread condition. (Allahdadi, KJ et al. (2009) Cardiovascular & hematological agents in medicinal chemistry, 7(4), 260-269). There is no available drug for the treatment of FSD. In June 2019, the U.S. Food and Drug Administration approved Vyleesi (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder (“HSDD”) in premenopausal women. This is the only available drug treatment. Vyleesi has essentially replaced the only other drug for HSDD - however, it has a long list of drug-drug interactions, including commonly used antidepressants, such as fluoxetine and sertraline. In addition, it has a black box warning regarding its use with alcohol, a combination that has been associated with hypotension and syncopal episodes. Therefore, there is an urgent need for effective therapy against FSD and HSDD.

 

About OT-101:

 

Oncotelic jointly owns OT-101 with its joint venture partners Dragon and GMP Bio. OT-101 has completed seven clinical trials including one phase 2 trial in COVID and two phase 2 trials in brain cancer and against pancreatic cancer. It has pediatric designation for a rare form of pediatric brain cancer known as DIPG. There are about 200-300 new cases of DIPG every year in the United States. DIPG most often occurs in children aged 5-10 years old. Treatment options are limited with surgery being contraindicated. Most children do not survive more than 2 years after diagnosis. Currently, the main treatment for DIPG is radiation therapy. Although radiation temporarily improves symptoms in most patients, it is not a cure. Paliative care or quality of life services help patients and families manage pain and other symptoms, promote quality of life, and making difficult decisions including treatment choices and end of life care.

 

When COVID-19 emerged in China, Oncotelic and Golden Mountain Partners, an affiliate of Dragon and GMP, entered into a research and services agreement in February 2020 to develop and test COVID-19 antisense therapeutics. In March 2020, Oncotelic reported the anti-viral activity of OT-101. The anti-viral activity of OT-101, in an in vitro antiviral testing performed by an independent laboratory, OT-101 has a 50% effective concentration (EC50) of 7.6 µg/mL and is not toxic at the highest dose of 1000 µg/mL giving a safety index (SI) value of >130, which is considered highly active and on par or superior to Remdesivir - a Gilead drug. Unlike Remdesivir, OT-101 targets not only the virus replication but also the virus induced pneumonia and fibrosis. Our Phase 2 trial was completed for OT-101 in South America. This was a randomized, double-blind, placebo-controlled Phase 2 study intended to evaluate the safety and efficacy of OT101 in adult patients hospitalized with positive SARS-CoV-2 and pneumonia. As reported in November 2021, the top line data was positive for safety and efficacy. For more information, please visit www.oncotelic.com

 

   

 

 

Oncotelic’s Cautionary Note on Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as “may”, “expect”, “anticipate” “hope”, “vision”, “optimism”, “design”, “exciting”, “promising”, “will”, “conviction”, “estimate,” “intend,” “believe”, “quest for a cure of cancer”, “innovation-driven”, “paradigm-shift”, “high scientific merit”, “impact potential” and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the company’s product candidates and the potential use of the company’s product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the success of the launch of a company with a DAO infrastructure, the success of the entity and the plans surrounding the pet and animal health, the ability for the Company to register the tokens of Pet2Dao, the actual filing of a registration statement and approval of the tokens as registrable securities with the SEC through a registration statement, the ability of the tokens to be tradable or any value such tokens may have if they become tradable.. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive and the company faces known and unknown risks, including the risk factors described in the Company’s annual report on Form 10-K filed with the SEC on April 15, 2022 and in the Company’s other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the Company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether as a result of new information, future events, or otherwise.

 

Contact Information:

 

For Oncotelic Therapeutics, Inc.:

 

Investor Relations

 

ir@oncotelic.com

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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�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otlc-20230309.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 otlc-20230309_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 otlc-20230309_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Mar. 09, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 09, 2023
Entity File Number 000-21990
Entity Registrant Name ONCOTELIC THERAPEUTICS, INC.
Entity Central Index Key 0000908259
Entity Tax Identification Number 13-3679168
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 29397 Agoura Road
Entity Address, Address Line Two Suite 107
Entity Address, City or Town Agoura Hills
Entity Address, State or Province CA
Entity Address, Postal Zip Code 91301
City Area Code 650
Local Phone Number 635-7000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false

XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000908259 2023-03-09 2023-03-09 iso4217:USD shares iso4217:USD shares 0000908259 false 8-K 2023-03-09 ONCOTELIC THERAPEUTICS, INC. DE 000-21990 13-3679168 29397 Agoura Road Suite 107 Agoura Hills CA 91301 650 635-7000 false false false false false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 20 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://oncotelic.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm otlc-20230309.xsd otlc-20230309_lab.xml otlc-20230309_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 20 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "otlc-20230309_lab.xml" ] }, "presentationLink": { "local": [ "otlc-20230309_pre.xml" ] }, "schema": { "local": [ "otlc-20230309.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 20, "memberCustom": 0, "memberStandard": 0, "nsprefix": "OTLC", "nsuri": "http://oncotelic.com/20230309", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-03-09to2023-03-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://oncotelic.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-03-09to2023-03-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://oncotelic.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-007365-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-007365-xbrl.zip M4$L#!!0 ( 1(;5:TG&LZ_A8 $-: * 97@Y.2TQ+FAT;>U<:U/; MR)K^[BK_A]Y430JJ;&-,(,-E4DLP(>1 \ $GV?FTU9;:5@^26M.2,#Z_?I_W M[98L&Y*S)V=FLF0S51FPU>I^[_?FZ.WX\N)5NW7T]O1XB)^"_CL:GX\O3E\= M;;F?>+KE'Q^]OAK^*F[&OUZ<_O)L:M+B0&SWLT*,=:)R\5[-Q;5)9-IQ7W3$ MC;)Z^@POXM71O_K>H4BDG>GT0-#2^M^A*-1]T96QGN%1H-)"V6>OCMY69 MN+D^^>69NM_?[V[_=[^_W?LMFST3QQ?C7YX]^^-8]"\@^<RODKK? MRKS0T\4?C,5;J&6[=9X65G;'96*L&)^]Z3Z?J$(>#L3(JE '12Y&!D]N2GNG M[V0L="I&>" +JP-Q(M- 66&FHHB4>&VE3O-")4^=,-\'>[OC2+5;8*GCZ+:0 M:2CJCSM"YV9J;)(+:97('+?UG7KJ:'\?S'N>A#*/#C_BD% 6VJ3M%K2LYMY MR)QTSLI,E04TL0"@JGCR6#]]WAV?77VX/FZWWIY?7-QT8"%C/>UUQ*6T022V M=SIBT!_LB(VSBZO7I^+]Z:>;3^?7IYOB>R'08FT4RA0. H6"1!%@Z#>(RU.E,C*2] MA?4WZ7.;T[ZY&.I-V2X8J-0%HHE-0M2-"/9V6N<)^ M\"MICI49"*M3)6:QQHJ\QG=X/CIK@ ZX3JX^G@^[V_O W(1R@>]24\(OA4R) MK)S$'EY"CGR>:+@\&$@KTYP,(6%Q9LV\B,0;&11 ?44J)C*XG5GL''8#$QM[ M(.:1+A0".-9(+[ #<4&T)/64E0LU3%9VH^.*MN*J+ )#HM5TJ.W6JD>=5!ZU M)RYT>@N5-P^0"L"3B0*K !E^B]"Y[A^+O M\A\::_';V&I5=C[V'DB?^(+PO894B7]7G(9>K\YKO1IYO3ICO>KY$"YGL]01 MV[OXM_=RKR>BHLCR@ZVMT.B>L;.M[7YO9V>_OQ6X]=N[_3U>^&29]<1EK<'D MX'&;T;3.9#7)7.?"@/=^96+R0LC9S*H\1^#'QC14,HRUPH,@TG$8&1.Z'45! M IOW($HBSV#X:)>T3!1,8BZ"6*EK',\Z&8P- )"0($@I9X/W,FCM"B[#(J\S$.!7 MT8 B4I#Z#!;2'1GKHH@IRC6,K8B@4!.E4B&!)C0LY-/9M&)):G)0RJJ$* G? ME"8SA=,BRN'KL+,4Q=QT%TK: MY8M6.B+&!%!!KA4OP0=3QOI#K;X1^)PS9:7-3%[K"7*CG&QL7I3A0LPENV$% M%I;$05I1B;_( 1?)+VDD"T62(?[3D"]UG[&>P6/'9-)S%VHUS/_,F?^I,_\4 M5+1; [&!F/]KXI!-\@0$&^LMI#3/2^7T"PX#H9TUB5A5DQZ\B!53"O#262Y8 MR4)&L-V::@N;H.@+0@WB6HB(O!DC([X2R"95H'$RSTT JP9R>67+R,O5 2D" M6*?C/8J.H:"9L;086Y0QPE48'@/]RNAKQCTU'"(QM-/2DBVI&.?CP17N98BD MX1W)EL"V06;R@I1T1M;'&23BTU?BVFZ!(5E=.OF,T28RS*6%7 "Q'U;@6X'O M9RO>WF'BT%0F\H/PF_#\RE*+,A/.N"ALW>ZZ?9AM'1<6M7,"-NM"65S$O%G M!LV<(LL+3!E3C@*%#0IG%B>+?U^S!*N.#'U:"*UE$S*T/?&Q- 2)"\#%R>F5 MRQ@CJ2WD@+2OSI]_*-NWJI@@@JW])[M8R%YAP'$1&W-+@@&9JYT ,>TQ,[HT MH>P[G.XV [U 9206.-XET>_9">#0<[RFB[(@-P?]?*MD3,Z'!(6TX1H^DJLW M50GB_?G;ZZH$(=%N;4RW;K>DN(0[0+3WH*#:V^QP-$\!. R#CY=O"I^7T9&_&GM+#[;W M?_Z9BC!7_Z7/3M^?NM?=VU;!Y1DD#):]SOHN0Q5+!'2*P[_M_?V!2W0#Y'LS M6HZP-97((&&4/@LG;3KH;^_Y'+F^T+)F-]\#Q.43&!K!OU! MO]<05K)5N5)L8;$/1?(6.3K#%"J5472N+,P8U67%2KK>C%7H79>2JZ:5K@I2 M#N0J1Y]ZBXTDRV<=5:C/J0F6J"2#T>9*A:L]KQM[RE-J%,B^KZT*%65AKD+- M%6PJ?G2*"('$K/8+_B.X @A>[/XD?C.(5L0=($(<(\XN1^*UQAE!E#JL+W2B MB;^5$_ KEJ5H1F,( @+N*U"2BM]P()DN@-3ZVVY=]?*A!S 08G+!:BN0W&AREN5Z,922";PZ.]L-JG#"9$,?B^UQ>$C0O%: M#&4A'Q..[?UV"ZSD4CW\C9BLX!^X5H+GEJ7PC=F%+54,9>:T,)"9G.@8KD_E MWYM;^H]N5[S1*@X/Q A:DUTNWZJZ&AX_K$"8FTT88]&$R;&PNW7 MW[V.$>**[=XN$,L1183 8WS\^N(4L>K%Q>AX.#Q_?_;+L_XS_GPS.CZI/E*?KEC?8VM\3?\C(N GR/D(92>0T=ON1$%K@%#&[&A.ANPQ MAJ-51K 8+<\:K>[>8.\6\=>Q].F+[9,!?UA:SAK)>[XXNODP>E5$1UOT4_Q> MPN"X8!D^;+O3M'"5<3N^8+L^Y03;-1)E*G-.JV,-$5^X(JU)J(^I4]43GWB9 MHL#:5 [-[^,,,I?/FGE'W>2LFINU01\-*V/>8^LO]OJ=?K_/5:3:TY&?FBAR MM_!5E%U7A:[1L(H;/J3L)SA\\+7CH+36.WOX=\6[4%8!LP-*QU3(JD^H=KEA MGT'^.^ BNJ&\W#+$^-V]W1O4[R,+'_1W^ESN+HPZNJA32?SWM913EN)GV@W =I.E<:NS55\RW" M6U/1(3_:^O"J5W%5^]H>$Z_=JMK5(;/[E*L)L1+#18ZL*N#27L67TP9?3H=5 M=L:=#ZIBR)@XF^ '(J'[DJ1%YVQ2&ZA0K='7Y6$8N' +@0!S0 0F+\B'O3E+ MHX@CCLT\AUB_Z.UT7_9_\NNI_1%"+ 1U : '>[V7W1<_KSY]63\E]NVL/?W9 M/Q4;9TK96ZKB7KZ[;+=4 >KTQ :Y<$*SM.*#1?;\Q@0E@J5,ZP-Q,WC1W^V^ MV-W;W\"BG7[_Y7Z78H6W9DYAGP]?G.:PH'#:'29(3;D(ZLNEH^'I[K*4Q?*V M;/UD5H+X@>H@@O2!=1 ]U6U&.I;E5)26QH']]^:X##S(X$+L_[W?W!YL(;Y;,RA;5J M&+R,8VB$#,2CL13AZ$Q(YANQ6 GFQ9P+]C M!"E1*$/=$7][U^3J_B8574)M[F0>E$3=YS)!.!*! 5%HN[P667MJ!L7:"J' M4+N19'71$2\W7B @'^SUNX,]TH@Q(P@ 4P-BW('S$D1RBK*L*4IG;BQT6L('YB Z&*B^L+D&*319%. AS> M,TO EW=9?D(TA$5T25*8'V M1SRP$!O(?0SJ$$UI>9??(:=KG9ZL%HR18R1\0)ES1Y9(QOTAR4WX53S%PB79II&]WU:7$M385\0QA!'>Q&* %PI.,4MD,3 /_O 12M-KQVD;: MDHK2DB C2/!60;%'T5QGIU0>7E?.N*S).DB;$[&_M]3JR8#?J/AQ&>'@25?* MOKMZ']=PR#[-$1KY0@]K*"GY:H$'\6B1TMR3K]B0:OF23J_9.Z"R1\R#*#F, MVS+:$7[.93EB0X,U5+E2U+7GIV25>3C1>=FY<<_%8/FRGZWQ70R>%/'ZWAB: M=$]AW)P->K32Q>9#NE(8U3-Y"F:Y#E@)>6"L5I%$^Q/):N]-PJ#J[-%!91F #)2\ZE3QXGLE4HNPL"^V#6Q&&O M,FFEFB0WP4Y^J.BB,7RBQA M<@?^6#FEC-+G81JPGU1IEO/U"<\\+<-%7T(Z7O7<%28?B=B3%A5K? MW"4AB;QU">MTJA&0%1"Z0.?,HJ7L+^D41(;AX?23#O. $@(_W-8W O]31.EJ M-2KM[IRVE#Q1C0=+Y3H4S]B[+?V2-J)=0J"IX M %[@@36\VBTF.$D/,F5],VFR<$L1P$(-"%=$W=0B,I2@-!R,%+O]GY##UY$? M+!M5&GQ"L7%ZLMO?)"!>]O;$\T0'UAS.MI*+*NU$@N0NX20X<:"J+R!;Z M";9M*D,U7YQIGIV4(I=3!00)R'NQ<7.^V6[1;!2_]7Q6'&[O@)KS2(.RFCPA M(MR0V4M'4"[A &:;0C4H2Q8J+T$$34F5$=G:PY21C*P,O?&X&B3(; MLK^UD8],SLTESAO916; DEER=M0'8J M\CU9J_K%\/D+W:+!CV[1CV[15TKO$IPGIRN-BVIN$(HN.Y4\RP3O_YX"4!AU M&)*YM&'WPD]^<6;!E]&>=)+Z?:3:Y I7: +"U8YXTY^CJ])3#WGJIF]O.8< M.R>?,"9*<@'.SSV/K+XC_W>CD/'PV("XP(^9\_#7BE/9XX +B-O[^[N4:<6- MK9&]N'2&<[O&D5@/8!%M^?'4H*A+C=60#L9"9_.9B.]8ZK\N>ONZ;R$5]U=-_Y?I\U;?MEO^:XM- (UZH[GI6ZR.@L[[''2=U MZ]]2-I[H/%G_WE4>'L(1:(J#'T!"&:;.&T^J-^8ZCM>_@T3=::X./]@?$DU- MC,X:/BZD6O_6CRP_ 9^."]\O21@YE9#2>OGZ30U=\SV;@A!50\ 0LR+?'^6 M=/-(3XOUIWP_(@\H6N,[311'/N223C)(Y_+N084%YTR^P[2\)N$*(\T8DFYD MD*)_49*\614/GW%?AC2XH1:K&NZUIN,";C\>7I5F"M-IJIVK('D-<1J ;:3O M07,#H=:DR@:\^XC DZL,KOG_[J//'RE_TGP=PPW&XH6ILFP]K+_Z%03N\A32 M$C/MU!>X"/X.W+G1^L"D%RE4? M*:BN7/MI7X!#EYY)PD*ZRN]K(PQI?=VD7%XV6GN?3.;K?*##9R1C=3 M/ 'J-R<+3YWEIC0/II4GFR?OM(S)<=VJHN$!/'HY@MU2QVQ]*_HTN&*0N,'< M&BK;ZB"F.UHXB;U#M;J2L\9;L2S3(*HN"E9O=-8WIX]N*6.U-NHFAL=7E-98 M":\ 2$O?Q*EVX"("?29>^L3('Y>2\;9\@:$&@GJ=5.9-8T8$6H7TCE&<\?_YXO)=1JZ@"H MF.>A][OR0*M[:<(-Y]HOUP,"-ZV-GY=?!T(I+(.S6_3J5?ON!9O=GKB5/IF.8NLGW> E+^?&=B2K4? -J\ZENF]=B/3]5= M8]$5%,A606(G5(W#BI"'KLC@URJ/U2O7,9@VJP8!?HDF1"FF\9,A."&E:@>+ MEW5&BL<^J(IOYE6 5D'6\?//K@Y>PTO;W&M72B,EA*%PA02_NNHZ- R-0JQ@ M3>H,>C730<:9$EM?<&.)JZX%DK2%=WP_<[F&R,I_'>,SUKI!TW@9GM)%?-<) MUWE6%FSM7+6\J;Y81>VGNFZ:U\KS&>^6]]JM,4N7%U7O8.F<##U\&4M?@CD JLGR\'UDW7_(]/429HC'Z=H"1*"[M_( MU%2EI\HPX/EQ9G7,?TE@T!^X M3C>WOJ<;T0CLM;KF6T\J@>\PR=S/DBSR-J MD>=EDM4>T-N=T)>K'P8WL"#W="_(V3WO'.'.8CGOK' Q-,KW9N@$LK;$6O#- MRP(DK,SXG"^8A&6D10&+3IUIG\; @4V@$W.A5Q&C&JQB2KG2(ZN\OZ%*^M,H MN/G BSJ59!0J 9WK_$?SY1NF_B?$]Z"@O[56,^O'Z,"WQ^(-U;._='WFX,FB M]L25YCQ%J%80>ZZ5N_"8/UEM5RNE/[X=';M]=F M%GBH- T]-FX4\/!N?O]8.J[:D0'/5,4OR2"UTJ.NH=2?-$A7WBG9PDQ5/;-J MW5;5256NQ':ULOL4'+;&N,%P7MT*P@P8LC_>7YU-JNO9]2=52UK24'6%'% - M2X@]U0OE:J&ZD^JDH)B7Z0C^+O;$_1?[V2O4*DD_CQ8GBRD6=Z@:S[C/IJ8[ M&1,*H$6UFE24K#NWVYT2E"858U7H41J-*W>IZIB*KB#3J_M64'$4!6S 0CVW M'=8Q;?^J):V5U$^V=.53K: _*0*F9HYD2C(@>B(.M1S-GB57F&D H\X$)5/I MXN:L-:XE@)4U"[A7],0 J]7*M7(CCPS-J-_,$?SG4',=L.9AR?[,'0Z8I@1[ M*+"_8G[_+M\2H89Y*-R,(EA?S_[U+J_94)<,UY>@5?A_A0(YY2SP]\DU MTP?DG [8/AGZPP/2/C:_W):K[V\_7_^[>OSAZ.@2?B#\I%!X9N-:]1:1O,T@ M=YL@]_Q^MO?&C;ZA=7WOE@$I _3P[TD(!K0WFV7!HH]OZ<=G./CV\JMDT&V2_CT%5U4;Z_[5#)U M6[TU$M?VH\B;?O\/FGF #]>);*A_H*I=.I% .DD$(9_FUH,?D]3T) &,9A?'\F$>2;$RHX M+&6&6,B@&1+)-PV-S!JGE,851P7!RB1L]4R9G/:)"53(*5'3[ZYJB,;I/B-/K3T^C8<,)UEOV=W#LL0=MF+I<[ MC+Y6NAZ0 94]'NX3K#K^[X @^15HP'M0Y '7,)EO_N=?E9WRP6$I:K[X4&Z0 MU&9T%0>L<$E[9L-,[P@/W-=]!*#\[WRFH",D3$]!BVB?O ^H=T>V84 E NX? M$%?8$5J+05)>*=8G-1"O@N)_P^Y7B?0$>YQK]_\4>*4,?&]J*51$P_0(A2X= M\ "VX"^,D9[ /9S!PT[S\WG[YN0X=WUS='-R?5CJP$QB]\W5P^3ZI/7YJGW3 M/KG.'9T?DY,_6A^/SC^A?HY,M& 6 M8%O&BL10)Y0?)>?_SM*T3GZHC&'YYF M$@EU>G'U*6=[1,4++;=&V5JCA<*Q\&*T,M #<.N-S>:) ?VW.JV-:GO;?QSM M@)WUC\V:]'CYYE[AEVF;9CS-:PGS DK2CRP05DU7@OY=[V,7[CZ)([ 3/73' M(FNW8@D&NFE<.2?6SS-[5ZW^?=S9DQ\:H[;WS;NJ M/=1YE^=#O>_#2 -HU_?I: 23SL)9NVX&L'SS$Y5>/]?8(MCK>B->(MC7JOZ/ M13,367+B9(D]=+AB/:YP^]=X_C)'E'SX^;VW&YP&PR"_*)MA06')U='GR^:;=NMXB[?-6\;'\657! _.W<3*DGL[A?. N*,?S M0*@B*F(>GDKXA,/*:T5 CX%-4;[ZIKB2'/D?;AIT&/A;_?N6FN&<10'\? M>CO-T-LI#Q@L3H?)V<15OFG_H>_I^Y:WMP!?W_28YHB^4*TT&N4UI2P=I60E MTPT=MEWTA&>X_BFR^>NDTQO];^?J]_KBR&8. /EFI5:H[>PV*CM[SR0B^)]< MCKT')F=5U ?488V@-[@*283N,TG^C"57/C?NN6EMU4S*"N$GN@9DGM[;IE7P M?\C0JR)Z5HPP6V(PX$J] 1K$S=$ ;:7;FOQ68,TVVE?7!M.3012($9.K3H39 M?=:2HRC.I,7Q7EHRMF1SM>WA58%]AK;V/J.M'?F^9$JY'V<\9)79FMK)^9_U M\^H=O?S879BF-F/P?+/:J#5VW,0L@HNA?R4HI[T ;G.%YV=__Z^?/ID-T- M@T5C-35^OMDZFH/0\[CE4BA-@__Q:+X;J=;=59?W_?N;_K>?/\[!)C-ZOMFH MU,J5-\LKS0V'-1Y^1Q*6CT_3^P\8*7=/0)S G!"=E<^717_'= M='(N]9]_[54KNP<4,DH<(7/5G7!#DB'>G<] M*>+01]>\D/ODH<^UC2+:F"?U4=H> >[SQR((>FP0#P@HV,AB@.R5_B%='F R@Q7H-EH%OH@ +0 &3"( TU#)F(5 MC(BBFJONR+1T#40'4#"NH20(-Q7. N(49 T-1TE95P0P.+;# V6.3EI%-C)8 MFWGQF>=\[ONV$TQ8D6\JQA)3YP,+F01=NAW"6+&-"#XJ5HL6OA'M M"!$P&IJK_FD%WM@[E*YB).I%]X$1QF,%MIU RXD;L/@#(*MQ>R M7:U;03%]#P##_SD5@:8I0<9,LYP'PBT_H(J,17AW4'VB=YKDEKT'] M\H"LP]XGV,QA1P]FBYX*K=;I$=V[O*N]J.AY#,^;D#L3M$ )L'B-!8X!.A$Z ME6U:J%13&J^]2,M0O,+N/N9Z+]H&\Z';G MN="VO>WNG]5/G]ML^T4%T'RXWH0@ O0*7@J_9VE"E6V_4-WH;#Y/+-FZ:\&T M_,2P%DPS[D%-"8"V4C&37Q1/4:O]6[M=[5T/^6N*IT?0_\X24 MJSM'2+U*K-%3!P2KZV]\%:PFMGC.>@:99'Z&(L87^LVVY3R%0 6OZ,/[;NO[ MEIU[4]G3.K,/$K[N\D/MQ2\_W& Z7!O7WB5>0)5ZC04<$ZY5Y!EK;+\\R>'T[X1A&O3YAR5X.4AW$*'R9B/Y5T&!?8(I*1XO7 MYI8Y:O^E(<5'3>R/%&C&"D;(*P\1U+//!6#D.*3 M1SZ5OK(Q5?X\[TIM@XZ]*VEY6R1CZGU;*SJ+3A><*SYCFLW,%I_*)K^489/? M>T%6'ZL,/AD*P\4[@'9_Q>@+ONFNV8#L M%O$^XF(2#2W^7EH,*P"QKSI; DP(9KF8^5@?O;L8(#PM?BH>Y'ZE?W, LWA ;B1G\=9O M1?(1##X8%A3/PDT\ )7R)LD:CBJDM6;(*?4T%+W'AP"KY(S=LP#= 91"E,Z]B#4HK@SO#9!+J$8U6E['O-L%M3>'0W+0=3UHANHJ(Q\" M#K-9)"U\J%,J-U.5.ORWL[M3-"\0JOU2R1?)4#VE=:@_7V^OJW+%X@.]Z3D(.=N[/;.%CN>)II M26T O?EP6@#HMW<.JHDP5E807\?RGM_3("M^K7!-K/WWDN++R&RP"F=O2TYG MJTM8H((@'5DRJIB4$^,_:S;9G1*H$2A,:4 B2V;\GJVIY@>FFM^@:Y\F]SO' M!%,U (-RJ">*+=&PFS/].I9(<9Z8=Q]YB'G+]DG![@AK%2X)UTSVB)R7V2,Z MR1Z13FURW+[\ 'UQ13#UB:LY$$H3VNMAP@#,88."Q&?4MR^Y>'T>^'TA?-LC MT;B'J2+L:$1%W#[[$N+QB(@5\_ 91W[Z0!/%BE,AT^HAO;&/0Y8(1(JV3:%-5]@ M:+PLK4#N ;';$0.N=8""4!A_PQA87X D&$>^&1Q[PRJA4#!/D@UP'HG/ MU8 &6\1Z\LD 9SV$.G;79W0-6U-GL' M;/9L G:[(ETI!B1+\D4PYB4>,B'SCX^3W&U_ M:9YIPD>S/?P$'-5'3=5 E]X74I!CH(%2PL/4 W[""A%JK7KL/G#\5T0/R?@! M*/A%Q0&HN" 4!%!_9)Z-0CA"8;8B,WXWEB:\P% /=)429=V9LF,B-XP$M$2;5B8\%FGCRH5] M @GYW,@RE]N$ZU@S$Q[PD=' A 7 PB(Y7H'H-D^T;3AV.&]_O$I.2=YCP)7JDYX 8RQ$L),<=S S?V)"*'LCQ\2^6]RWG.>9] T 6\1( M] PE%;Y,]M2X(#.20=6T:S1FKY>!7A\8Q'/@U#;E2N)J#X- MRE-$0Y<';+QMH#!Q.JM1*\<10GO/C,S<,J=" M QO+-'6,E:Z?.B3IQ?LCBA9%RJA]@D3@L%1 M+@/5W+0O+C@U#>U63CR^;;B%]Q5 !IO7UPR '98HX)CT:KP0 ,38U,Q HV(/ M55L+T"M&I:Y9;R+_@*= *?<+9VYK-FF3!\:L6-(5BAIL0.W=:)3:)MV>^?/ 2/$-#N/8>4B-QMTK M#%84/@@,][121R7"%Z;3"=NMY),Q+:8_/F0^JG[ZSYRKX^P:-=W60O_H,UC" M'%-;ZQDM@*P&LPILFL%'G\V4N8\HK!6L0$!ERB&BBN1T/D$DFZ[O'C5VJ\IF MKVFJH60]Z#+9B:=6,I=>MJFJJ2*K#O.!(\.C,U3UQ]1@G'W&^]>7(N[US>N> MF)M18&QOO5S?Z&QN5#>)RS5KQMI*7^+(.:@ %=BD3+@PTRQMQ4Y&W1H[)R>+ MXYM(9).*7'B,^=9[S] 39/PO4)B:$%3O.Q1!BR-A68)I*K.]MU'#H)@-Q[X! "DRL4Z%>* M)9I8"OW8V%L/^,LYA@QC9. :;^O=.(!=.G@EO\TZ0>0;B@QL+&]DX.GX7L!U MBG^!79RFK=8A@LNA$FWXF[G4FJPET'>40"^;L&):NME.7U9,.:WX5!=9HYN7G[W%@I;_]8S/CRC]1@%(*Y)HTW'IBDQDMNP#VF MFA*D,++!!AWF^RZ"S#G[V^;>&_GC_=79V-6[^6.MSLKD?K(7MLOXS-K437;S M[=7=%4_>T:\>D MCE*E]',6=C1^0WV@08_$/=H5_5HJ9S+7^0GHRDVD\(#>C M" XDK3#O0.""0+M5)\+G,!JYC)^T@I+"F\B0<"L67L&+RS84DVP7-7#;T#A MNOWA_.CF\]7) K%8-G'TTBE0,M=AJK7%DMEE\BZ*.P&7P,M5BA[9-9 +'6$/P(V M*?7U(&C^/U!+ P04 " $2&U6O_[7 U(# "\# $0 &]T;&,M,C R M,S S,#DN>'-DM5;;CH\--'9'[-SQBC$PHL;*"V"/ 9[XL#](-$T$"GP$$2+>0!NB4L ML19Q0AE(="RBF($&X\@B-=!.Q=\+$,8;Z-X"#X6\N3J;Z#YH':N&ZXY&HPH7 M3V0DY*.J!"+:3+"KB4[41,T;>_EO,_HY5<&$7-\]C]7>^(K>#X#O)VW"1^J. M1-^'O'Y[NOHU[]X^[O>=?^OK4BUCW9_^E?5(=]+ZTLY!-%3Q M1) Y#*Y:CJTO+V]4JP@Y<*N>Y[OWYYUNBG,R8&/,*']@OH$G+< MDZR0KKG6W2,*)LK&2U_!4ZXTX<$**JFQ2N(4/*P5<&-="9W3M%3]'(-:K9JZ MY@@7UYWC"5:8(=+ :&#;TL)J7LVKF^%B$ '7)T)&;>B3A)E,A@EAM$\A=) F M<@#:]IF*20!OR17=2C@7IJG-9.46:XMC:KK6&#XT[?$VI&!P;;)&=F'&:8VX M];K'PMP)#J)AR\F65L:(ID(A]"FG:;1\<'R$[9@DMC2S3"E-=Q$\(Y$H""_X M8;J.)2C#2]/O&$-.S"%K2 %A0<+*<::IK*3DAF*;IAM7#,<5]%$Z5 U[^"U' M47NM.;GM04*_Y0C- ERMB;L5W'-KXQ5.,VT3!+3'2B7 M1,';(HDU%_.J^&H=W"YL"U4W#3JYBO.;?Y.@*SDN,*T*R[M2F'MGRB;T+TVY/L@.P;;"MF&WZ(+EX*M:H.EF M:F;Y%U!+ P04 " $2&U6&:M):/X* " A@ %0 &]T;&,M,C R,S S M,#E?;&%B+GAM;,V=76_CN!6&[POT/[#N30N,XXF#;9'L9!<93[(P-INDL6>V M[:)8T!+C")')@)(3^]^7%$59HG@D)45)SL6,1WP/]5)\3%)?QY]^W&U2]$)X MEC!Z/CH^^CA"A$8L3NCZ?/1U,;Y8S.;S$D39"WYE_"D[ MBMAF6(6+'.?;K*KMX^YC^4>%?TH3^G0F_UKAC"!QO&AVMLN2\Y'<;[G;UY,C MQM>3Z<>/QY-__G*]B![)!H\3*H];1$8Z2M9BBSL^/3V=%*5:VE+N5CS5^SB9 M:#M5S:(TZ=#7G&3)65;8NV81SHMN[]T- A7R?V,M&\M-X^/I^.3X:)?%(WWP MBR/(64KNR0,JFGF6[Y\%2EDB21B5VQXY>;";23F?R/@))6N/X_-* > M[[P)2Y;C]%WFZY'.;=^0]QWQ0YS[(RW&>?*^(UV+_+_8SMN6WWQX[<&1;++Q01&8FU25M$Q A=[*":&LNZJ=A8UZDWE:,YXN^UR9BSJS$ATM&8O MDY@DHN[I5'X8RP]%L\5_?I\QL1*X6&4YQU&N:RJ:<3ZRE$],2U)YP;4OS*.> MQI6*2<3$U/2_IJHI7AT7L C#:D'&2L2V/R)MZ MI>X6.DJEHTTJ%'))1>CXZV+T0Z%!OVG5?SY-#K4XZ&BQ!-IN",V7HD9+"YK% MKKK99DKW>+H@M(M3N_) M,^-=^#1EKJFQF31AJ6N"8L1B#$1#:9$2>R+B'UMQQDYXNN^%HJ5TS05@U43# MD 5%A]T;"$@E]\O(DF.:)7( ZX6D+75^N@&8;9UZ&+J@. ',P:R:%MBPR4M;&10QH#V0F2("E2'A8'/Y(E?G8IDTL+$UO4]X M6K:[^*G$P2)D.AQ(41&&9)PGDFJW(7H8:BE=TP-8-;DQ9$$18_<&LJ+DJ-#[ MA^22QH,0J71^ #%LVO$H10'"T736AX90^P3C*LDBG"HO5V);UM$\B]8U(*!= M$Y*6,"A0('<@+"I ,U.$> 7F7P3S8;C4E'Y@:5FUHU+) @3%]-:'B=1[@62V MY;SA&IYQ8*FSF[(]9JO[LX N"%!ZS+7NVBIY Q1/,] ES9-\+Y^GN]EN5H1; M&M>6N&(#,J>9,,N#8 $P93*@9$CJD!)ZZ7E]EX#F\B%&L#FFS"T!=I--"IJ: M@$BP&@-H.&B+9TJ]$#$3(Q/'Z9S&9/VTUF '% Z'0[! @20:@9Y1.D.8T8?V:UQQUF;"L& MP/V,Q? *I2?*+52#FM!$JS,D(,"&^ 0P:X1^4,^D(";?XRDJ0+(&+\1=Q+$X M4%GYSW5"R3'8?JO6+5T==IM,680!D02[ _@IE1_T!R1CT"T-!9KI&YHZ]0_- M="@TTZ"AF;X'FN4K"P2:DS@ %, M6ZDQM.&A8S?8QT^U(-9Q7L<:M2CO_9)HF9]1IFG2/L0H37B0-(WU#BY*[1.) M.Y;E./UW\MQY(FX7>\'#:M@*24,9'BHV>WW J!@D@GR<6)>XRAL:UE?)C')W MKP!;;!U> :X5!@&!S5'[%6!U]42)7'>S9)03#(P(S6)GG6PQ5?5QK2R,+FX; M:O5P\;T6&A]?9)G=);U[9!1^0* M<=73D#G=VV9Y$#T.F#)[O9"A0N?I:KS, M,)'9A^]:F;.9W;133>2Z((C>-=VTIFE=[K@W?^5)+O8\8YO-EI9W>6S/#0(Z M5[W<:5/WN%441.]W.3-)*+6H*7:,Q8*E293D"5W_(DX^>8)MK;*)7 $!&]0T MM!5!H #:,CDX")%6.H;@CA,)(1$=4;P$*!,+\=N'!^MLWR5V!46_80T'K P" MDEY[)BPB8!S5(I *046,7VSF6;8E_$WP6$(\(02:!T!JZ4/$"3+9"Y4*],G6 M@D1;,3_NCZ>K99*GMI/+ML39G 28JV8DHSP(-@!3)@M%&6(/Z'CZE]5?D8YR MW/TW;,FQ3!Z[V&]6+ 6R3UE5KB#HL*@YL$B"0 'V9=)PPU I14KK(SM5PZRE M.4:Y*P"LMG37-PJ#Z'2;H]:7O]'7GH;\RUWT*$P1X(4$N\SUT&\S:0[_=4T0 M"'08:YV4E%*DM3Y>2#A,6>O^1<#:VR)@W;,(6(>X"%@/702LO2T"]&Y5BA Q M+MVNTF2-@>2$G6K74'18-OFP2(-"!?8'CAE5"#K$N,YH6:0XD^GY^:;8_Y7X M8&DEH'.6T[++9I74TB8*@I$N9ZVTEBKI7$V,I-HU%]LXR4FLS%PE%-,HP6F5 M'M%V1;P_Q!DM \U7X/3HPV!HF,D63BI,YS*L @^I+EU?2EK=/S/38;CXT XB#P&F(0^#1&1DT?I)12(>55\*\D/2- MI5N:8UZ\2\YM(Q.@UL8KR](IE3N3O120OY O.<>D-;"\D M=_U299=I\VU*FS8@A#H-@N]/5C$R50S63'E+&<-G8JFU9AU/B1LJ]XEC6A;; MN6,J24!XV'QU9)#A2&N]L+#8X#3]O,T22C)X(C)4;EFP6FRRT) $Q(+-%\!" M(45:ZX6%RPWA:S&]_<39:_Y8YF<%VP:HW;+1:;G)B%4:$"M=_@!F= A2,3JE MKA]X=H>$XBK+(MQ2B]0Q-J!9@YF6+B1@(',M6E(2R>LM-RQ'2X:^9@3ECP1= MEC]#5\\$K^KQ]4LC421?B%"KDPWXMD-_B"N"AIK7'/7I@Z!IH$F3J2*L>7)=!"(9 MZ3.;43VY/;S$:X@.,>6U[1K*\@R @ MJNH!1YA1 52B_]_QG3)[Y]SJ/]'6<1(?(IJZP:K?JN MOPV,=LO,FYK4I&E0:$":9G$&%,?@J>&>0X]L+ QI@W&3HB @(O0$VH1L.120J0C\@%8QJT9[.S[)# M%D 2?][?DP?"Y7L'2[++/XL=/76<80R(=7WV-K@YYLE<;V 0$+[5+72JEZ%Z M!6@EGQ$KJT"_R4I048OM]\OKFZ[%)[%9;Q)_K7!&Q);_ E!+ P04 " $ M2&U6,3Q[%%@' #75P %0 &]T;&,M,C R,S S,#E?<')E+GAM;,V<37/; M-A"&[YWI?V#5LRQ+:IO:L9NQ%2NCB1.[EI.TO60@$I(P!@$- %K2OR] BHH^ M"'!]X=H'6Z86P+[/@B"7 'CQ;I7RZ)DJS:2X;'5/3EL1%;%,F)A=MKZ,VU?C MP6C4BK0A(B%<"GK9$K+U[J^??XKLS\4O[78T9)0GY]%[&;='8BK?1I])2L^C M#U1018Q4;Z.OA&?NB!PR3E4TD.F"4T/M%T7#Y]'O)]TW<=1N ^K]2D4BU9>' MT;;>N3$+?=[I+)?+$R&?R5*J)WT2RQ16X=@0D^EM;:>KT\U/4?R",_%T[GY- MB*:1Y27T^4JSRY9K=]/LLG\BU:S3.SWM=O[Y=#N.YS0E;28^4[FQKMM^R@/V.)YJ=Z]R]6QD3DX>]MIG(:^'^ M:Y=F;7>HW>VU^]V3E4Y:)?RD5DO;,_4S'6L5M39:WBAJ*;"Y%IO M[8&](G1E;'^B25F1:Q_LFF'&66^Z2S=JN[Z5I;8Q^[&PW'A2^L)EO-<\=S&0 M!UK+_IR3UC0^F+1UECMU+[%H4^[4;M2<2150I5E7=9%5+P7J^.NN;'H+(BR%;7C M.>/;,$^53'UT-B2DQ]%=4+:)9FA>V?83Y\.0DUDUS@,3(,\N!M!*-5A$WU,= M*[9P7&K [ED"^?90^59H:QAS>>X\T!ES_CI7W 67NH/A<<%3! B^CSE2!-4B M1>!*B(SP![J0J@;\OB60]V^8O*NT(6'^.R/*4,77$-)'QD#8OV/"]BA$XOVH MB-#,\8$ /[8&$O\#]<;#HQ$)^7A..7=)'!&@7EYE#\3^!A.[7^"_T@M4@3NJ6(RL9=T!6!_9 RD?H9)W:,0E?>-2*"TMZ;@ M_ "HXK>&(D=)0.M$-LS\1AAFUNZI_^6D(9H^2:(7$HG =6CR)\)!*Z^DC7(=!'IE#2*#EF4!X* MZGO%4J+68Q;7#QK'ME#8*)EE6" *[4>R&B56%9NR8CJP'KJW")0]2EH)DHL2 M@I&(I5K(G.DH?6RGPEV/LOP]Z'8T?)16ME8F(?V(]WZE$N M/3/07F,HKQ6%ROI?:$/X?6]3=25;;0YDC)JXAH4T_8"SB[AY:^)82'9A ^:+D MJI5RFD;J(JPH\7???0LH4)0$M$I,PSQOI9O[F$L1?!Y[; 7EBI))^D0U/?"Z ME<3:>^KO? U>P88RK![*:!CC-\6,]6 @TS03FVB%Q:&/O##3VSEXX]J)D?#Y12&R+M>'V MC+J;<#8C_IUDP0+@?3:8Q -2F]Z_EV_Y;S_C7+^4L+O+0*- N(<8HU^&9R?"<^8$AE#;B4MA*:2B0QRGA_#K33% ='%L.#*&0$=>\5DI#@7R34C6S M@]H')9=FOMG;&8+M*0"%CKBR-2@5!_[JQS[R8O];D'R%-?CM!(C8O2*Q7KL1 MQVXA17$E%PE1'NHA>RAWU(V5?J$-D[\SJ@O!8T"2KH* M%8US;=W9R1^\M.[907DC)J95PG#V3&43SN(AER1X7[YG!N6+F(56R$+!>TW$ MD\H6)E[?*QE3ZJ9/]/9L R1$P J@(4',3U^$ N=Q@4Q3MYE(QD_CN16M[S*3 MO[_4^A=\:! L!PT-YB9.@'"DNR#]8Z,73:[7#W1*E5NF\$A7YMHV]!2^*0(4 MA\8']8U"8 P58;KH'.FZM0?<&VJ+;]PO]Q96>^1_4$L! A0#% @ !$AM M5K2<:SK^%@ 0UH H ( ! &5X.3DM,2YH=&U02P$" M% ,4 " $2&U6Q2 )9J<7 #ZP0 "P @ $F%P 9F]R M;3@M:RYH=&U02P$"% ,4 " $2&U6O_[7 U(# "\# $0 M @ 'V+@ ;W1L8RTR,#(S,#,P.2YX&UL4$L! A0#% @ !$AM5C$\>Q18!P UU< !4 ( ! MJ#T &]T;&,M,C R,S S,#E?<')E+GAM;%!+!08 !0 % #8! S10 " ! end